1h Free Analyst Time
The global janus kinase (jak) inhibitors market is forecasted to grow by USD 25.25 billion during 2025-2030, accelerating at a CAGR of 23.1% during the forecast period. The report on the global janus kinase (jak) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of autoimmune and inflammatory diseases, oral dosing improves patient adherence and convenience, shift toward personalized medicine and targeted therapies.
The study identifies the technological breakthroughs driving product innovation traction as one of the prime reasons driving the global janus kinase (jak) inhibitors market growth during the next few years. Also, rise of isoform‑selective next‑gen jak inhibitors and increase in combination therapies for enhanced efficacy will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global janus kinase (jak) inhibitors market is segmented as below:
By Application
- Autoimmune disorders
- Oncology
By Product Type
- JAK1 selective inhibitors
- JAK2 selective inhibitors
- JAK3 selective inhibitors
By Route Of Administration
- Oral tablets
- Injectable therapies
- Topical formulations
By Region
- North America
- Europe
- Asia
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global janus kinase (jak) inhibitors market sizing
- Global janus kinase (jak) inhibitors market forecast
- Global janus kinase (jak) inhibitors market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Application
9 Market Segmentation by Product Type
10 Market Segmentation by Route of Administration
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global janus kinase (jak) inhibitors market: AbbVie Inc., Aclaris Therapeutics Inc., Ajax Therapeutics Inc., Alexion Pharmaceuticals Inc., Arcutis Biotherapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Celon Pharma SA, Eli Lilly and Co., Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is technological breakthroughs driving product innovation traction."
According to the report, one of the major drivers for this market is the rising prevalence of autoimmune and inflammatory diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aclaris Therapeutics Inc.
- Ajax Therapeutics Inc.
- Alexion Pharmaceuticals Inc.
- Arcutis Biotherapeutics Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Co.
- Celon Pharma SA
- Eli Lilly and Co.
- Gilead Sciences Inc.
- GlaxoSmithKline PLC
- Incyte Corp.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceutical Ltd.
